Essex Woodland Health Ventures’ New $900 million Bio Fund

Essex Woodlands Health Ventures closed on its Fund VIII today with $900 million to invest “across the spectrum of drug, device and service companies in North America, Europe and Asia.”  The In Vivo blog points out that this isn’t exactly new news, but it is still good news for companies that are now a big step closer to seeing the money deployed.

One Canadian connection I was able to turn up: Dr. C. Thomas Caskey is an Adjunct Partner to Essex Woodlands and also sits on the Genome Canada Board.

Bookmark and Share

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <pre> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>